Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A role for VEGF as a negative regulator of pericyte function and vessel maturation

A Corrigendum to this article was published on 26 February 2009


Angiogenesis does not only depend on endothelial cell invasion and proliferation: it also requires pericyte coverage of vascular sprouts for vessel stabilization1,2. These processes are coordinated by vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) through their cognate receptors on endothelial cells and vascular smooth muscle cells (VSMCs), respectively3,4. PDGF induces neovascularization by priming VSMCs/pericytes to release pro-angiogenic mediators5,6,7. Although VEGF directly stimulates endothelial cell proliferation and migration, its role in pericyte biology is less clear. Here we define a role for VEGF as an inhibitor of neovascularization on the basis of its capacity to disrupt VSMC function. Specifically, under conditions of PDGF-mediated angiogenesis, VEGF ablates pericyte coverage of nascent vascular sprouts, leading to vessel destabilization. At the molecular level, VEGF-mediated activation of VEGF-R2 suppresses PDGF-Rβ signalling in VSMCs through the assembly of a previously undescribed receptor complex consisting of PDGF-Rβ and VEGF-R2. Inhibition of VEGF-R2 not only prevents assembly of this receptor complex but also restores angiogenesis in tissues exposed to both VEGF and PDGF. Finally, genetic deletion of tumour cell VEGF disrupts PDGF-Rβ/VEGF-R2 complex formation and increases tumour vessel maturation. These findings underscore the importance of VSMCs/pericytes in neovascularization8,9 and reveal a dichotomous role for VEGF and VEGF-R2 signalling as both a promoter of endothelial cell function and a negative regulator of VSMCs and vessel maturation.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: VEGF inhibits PDGF-mediated angiogenesis through VEGF-R2.
Figure 2: VEGF disrupts pericyte coverage/VSMC activation through VEGF-R2.
Figure 3: An inducible VEGF-R2/PDGF-Rβ complex forms in VSMC.
Figure 4: VEGF loss attenuates VEGF-R2/PDGF-Rβ complex formation and tumour vessel maturation.


  1. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005)

    ADS  CAS  Article  Google Scholar 

  2. Andrae, J. et al. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22, 1276–1312 (2008)

    CAS  Article  Google Scholar 

  3. Ferrara, N., Gerber, H. P. & LeCouter, J. The Biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003)

    CAS  Article  Google Scholar 

  4. Inui, H. et al. Differences in signal transduction between platelet-derived growth factor (PDGF) alpha and beta receptors in vascular smooth muscle cells. PDGF-BB is a potent mitogen, but PDGF-AA promotes only protein synthesis without activation of DNA synthesis. J. Biol. Chem. 269, 30546–30552 (1994)

    CAS  PubMed  Google Scholar 

  5. Vincent, L. & Rafii, S. Vascular frontiers without borders: multifaceted roles of platelet-derived growth factor (PDGF) in supporting postnatal angiogenesis and lymphangiogenesis. Cancer Cell 6, 307–309 (2004)

    CAS  Article  Google Scholar 

  6. Pietras, K. et al. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5, e19 (2008)

    Article  Google Scholar 

  7. Jechlinger, M. et al. Autocrine PDGFR signaling promotes mammary cancer metastases. J. Clin. Invest. 116, 1561–1570 (2006)

    CAS  Article  Google Scholar 

  8. Song, S. et al. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol. 7, 870–879 (2005)

    CAS  Article  Google Scholar 

  9. Lindahl, P., Johansson, B. R., Leveen, P. & Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 11, 242–245 (1997)

    Article  Google Scholar 

  10. Nissen, L. J. et al. Angiogenic factors FGF-2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 117, 2766–2777 (2007)

    CAS  Article  Google Scholar 

  11. Abramsson, A., Lindblom, M. & Betsholtz, C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112, 1142–1151 (2003)

    CAS  Article  Google Scholar 

  12. Sennino, B. et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of PDGF-B by selective aptamer AX102. Cancer Res. 67, 7358–7367 (2007)

    CAS  Article  Google Scholar 

  13. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844 (1993)

    ADS  CAS  Article  Google Scholar 

  14. Hirschi, K. K. et al. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ. Res. 84, 298–305 (1999)

    CAS  Article  Google Scholar 

  15. Hirschi, K. K. et al. PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol. 141, 805–814 (1998)

    CAS  Article  Google Scholar 

  16. Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985–1000 (2002)

    Article  Google Scholar 

  17. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005)

    ADS  CAS  Article  Google Scholar 

  18. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 2, 145–147 (2004)

    Article  Google Scholar 

  19. Grunstein, J. et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 23, 2800–2810 (2004)

    Google Scholar 

  20. Eliceiri, B. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915–924 (1999)

    CAS  Article  Google Scholar 

  21. Alavi, A. et al. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 6, 2766–2772 (2007)

    Article  Google Scholar 

  22. Fong, T. A. T. et al. SU-5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99–106 (1999)

    CAS  PubMed  Google Scholar 

  23. Klemke, R. L. et al. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 137, 481–492 (1997)

    CAS  Article  Google Scholar 

  24. Luo, J. et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nature Protoc. 2, 1536–1547 (2007)

    Article  Google Scholar 

  25. Söderberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature Methods 3, 995–1000 (2006)

    Article  Google Scholar 

  26. Jarvius, M. et al. In situ detection of phosphorylated platelet-derived growth factor receptor β using a generalized proximity ligation method. Mol. Cell. Proteomics 6, 1500–1509 (2007)

    CAS  Article  Google Scholar 

  27. Amoh, Y. et al. Hair-follicle-derived blood vessels vascularize tumors in skin and are inhibited by doxorubicin. Cancer Res. 65, 5352–5357 (2005)

    CAS  Article  Google Scholar 

Download references


We thank D. Stupack and D. Schlaepfer for advice and review of the manuscript. We also thank A. Tomar for assistance with the PLA imaging; C. Heldin for the PDGF-Rβ complementary DNA; and J. Desgrosellier for processing pancreatic tumour samples. This work was supported by National Institutes of Health grants R37-CA50286 (D.A.C.) and CA082515 (R.S.J.), and by a University of California Academic Senate Grant (N.A.). C.S. was funded by the Deutsche Forschungsgemeinschaft (DFG STO 787/1-1), and L.M.A. received an Institutional Research and Academic Career Development Award postdoctoral fellowship (National Institutes of Health grant GM 68524).

Author Contributions J.I.G. generated mutant receptors, performed biochemical and cell imaging analyses, and prepared the manuscript. D.J.S. and E.M. assisted with experiments and manuscript preparation. S.G.B. performed angiogenesis assays. L.M.A. assisted with adenovirus production, cell isolation and tumour staining. J.H. and L.S. performed RNA analysis and assisted with biochemical analyses. C.S. and R.S.J. generated, implanted and harvested fibrosarcomas. D.A.C. and N.A. supervised and directed the project.

Author information

Authors and Affiliations


Corresponding author

Correspondence to David A. Cheresh.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-12 with Legends (PDF 7521 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Greenberg, J., Shields, D., Barillas, S. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809–813 (2008).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing